Fujifilm Kyowa Kirin Biologics has announced that they will jointly develop with AstraZeneca FKB238, a biosimilar version of bevacizumab (Avastin), an anti-VEGF1 humanized monoclonal antibody with established efficacy across a range of cancers including colorectal and non-small cell lung cancer2.

China Bio news release, Aug. 8, 2015